BANGKOK, June 13, 2025 /PRNewswire/ -- Ultimate Game Co., Ltd., a premier Thai-based online game publisher, has unveiled a bold strategic investment exceeding 100 million Baht to solidify its footprint in Southeast Asia's rapidly expanding mobile gaming sector. The initiative underscores the company's commitment to delivering high-quality MMORPG content and driving sustainable regional growth.
Mr. Attachet Chaichanasongkram, CEO and Co-Founder of Ultimate Game, shared the company's vision for 2025: "At Ultimate Game, we are dedicated to offering premium MMORPG mobile games that align with the preferences of Southeast Asian gamers—over 82% of whom prefer mobile gaming, with 65% favoring the MMORPG genre. With more than 15 years of industry experience and the support of global partners like Google, we are confident in our ability to deliver engaging, data-driven content tailored to the region's evolving demands."
The company continues to build on the success of its hit title LUNA ORIGIN, while preparing for the launch of several new titles in 2025. The sizable investment will be directed toward marketing and operations across Southeast Asia, with a target of attracting over 1.25 million players during the launch window.
To support this expansion, Ultimate Game has significantly scaled its multilingual Customer Service operations—including Thai, English, and Bahasa Indonesia—by integrating advanced support technologies and prioritizing exceptional player experience.
"Our long-term ambition is to become a publicly listed company within five years," Mr. Attachet added. "We aim to be a top-tier mobile game provider across Southeast Asia, with at least two major game launches planned for next year alone."
Mr. Kodchawara Vanichayapron, Chief Marketing Officer and Co-Founder, outlined the company's go-to-market strategy: "Our 2025 marketing roadmap focuses on penetrating the Southeast Asian market by engaging three core gamer segments: Hardcore MMORPG enthusiasts, casual mobile users, and esports-driven competitive players. We are aligning game content and community strategies with localized trends and mobile-first behaviors in Thailand and beyond."
The mobile gaming industry in Southeast Asia is projected to grow at an average annual rate of 7.41% between 2025 and 2033, with Thailand expected to see consistent growth of 7–10% per year. Therefore, Ultimate Game is implementing a comprehensive Localization strategy—customizing content and user experiences to meet the specific needs of each market. This is supported by a data-driven Digital Marketing approach, utilizing advanced analytics tools in collaboration with global partners such as Google and Soul M Game to precisely target key demographics. The company prioritizes games with strong IPs, stable infrastructures, and high potential for long-term community engagement, while also leveraging technologies like the Unity Engine, AI, and Big Data to optimize both development and marketing performance.
In 2025, Ultimate Game aims to increase downloads and active user numbers by 20–30%, focusing on brand awareness, community engagement, experiential campaigns, and especially the new MORPGs.
Stay informed at: www.ultimategame.net
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ULTIMATE GAME COMMITS OVER 100 MILLION BAHT TO ADVANCE THAI GAMING INDUSTRY AND EXPAND ACROSS SOUTHEAST ASIA
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
